TAM / SAM / SOM Market Sizing

Clarify the unit and refuse the household-count trap

The first correction is that 67 million households is not a market size, it is a population count, and the framework demands annual revenue. The revenue unit here is a blend of two very different flows: hardware, which is a one-time purchase amortised over a roughly five-year replacement cycle, plus a recurring subscription. So revenue per active household per year is roughly $2,245 divided by 5, about $450, plus $39 times 12, about $468, giving roughly $900 a year. Second correction: subscribers are a stock that decays with churn, while sales are a flow, so any three-year subscriber number must net out cancellations rather than just adding gross additions.

Build the TAM top-down, and label it as a ceiling

Start from roughly 130 million US households. The honest outer boundary is households that spend money on structured fitness at all: US gym membership sits around 60 million individuals, which maps to somewhere near 45 million households, roughly a third of the country. At about $900 of annual connected-fitness revenue per household, TAM lands around 45 million times $900, or roughly $40 billion a year in the US. That number is useful only to answer 'is this category worth caring about', and the answer is yes, but notice it already assumes every gym-going household converts to a premium home bike, which nobody believes.

Cut to SAM with four named, physical filters

Filter one is affordability: a $2,245 upfront purchase plus a $468 annual subscription realistically needs household income above roughly $100,000, which is around 30 percent of US households, or about 39 million. Filter two is physical space, because a bike needs a permanent square metre of floor in a home, which knocks out a large share of urban renters, call it 60 percent surviving, leaving about 23 million. Filter three is modality preference, since cycling is one cardio format among running, strength and classes, and cycling-first households are roughly half of the cardio-inclined base, taking us to about 12 to 14 million households, which is almost exactly the 14 million management themselves published. At about $900 per household per year, SAM is roughly $12 billion a year, not the $40 billion TAM and definitely not 67 million anything.

Estimate SOM against the constraint that actually binds

SOM is SAM times winnable share, and the anchor must be an operational limit rather than optimism. At IPO Peloton had roughly 500,000 connected-fitness subscribers, about 100 showrooms, and, critically, its own last-mile delivery and installation network, because a 60 kilogram bike cannot ship by parcel. Delivery capacity is the real ceiling: a two-person install crew handles roughly six to eight bikes a day, so the fleet size, not consumer desire, sets how many units can land per quarter. Combining a rising customer acquisition cost with that logistics ceiling, a defensible year-three position is roughly 2.5 to 3 million subscribers, about 18 to 20 percent of the 14 million SAM, or roughly $2.5 billion of annual revenue.

Cross-check and benchmark before believing yourself

Sanity-check that 18 to 20 percent share: winning one in five of every affordable, space-having, cycling-inclined household in America inside three years would make Peloton one of the most successful consumer hardware penetrations on record, so the number is aggressive, not conservative. Cross-check the churn drag: at roughly 1 percent monthly churn on a 3 million base, you lose about 30,000 subscribers a month, meaning gross additions must run over 360,000 a year just to stand still. The events that followed are consistent with this arithmetic, since connected-fitness subscribers peaked near 3 million even with a pandemic tailwind that nobody could have modelled in 2019. In other words, the sizing framework predicted the ceiling that a demand shock could reach but not exceed.

Flex the two drivers and land the so-what

Only two inputs move the answer materially. Price is one: the later cut of the base bike to roughly $1,495 lowers the income filter from about $100,000 to about $75,000 and pulls perhaps 10 million more households into SAM, which is the correct mechanism, a price cut expands SAM rather than share. Churn is the other: at 0.7 percent monthly the same gross additions support a materially larger base than at 1.2 percent, so retention is worth more than another showroom. The committee conclusion is that the business is real but the valuation implied a subscriber base well beyond the 2.5 to 3 million the SAM and the delivery capacity could support, and the single input to verify first is monthly churn on cohorts older than 24 months.

Clarify the question and the unit before touching a number

Say out loud what you are sizing: all India, annual revenue in rupees, preventive health-checkup packages only, which excludes doctor-prescribed pathology and radiology because those are a different buying occasion with a different payer. This is a flow, checkups sold in a year, not a stock of people who have ever taken one, and the buying unit is an individual adult rather than a household, since two working adults in the same home buy two packages. Confirm whose market it is: the fund cares about the organised segment, because a standalone neighbourhood lab is not an acquisition target or a competitor the chain can take share from in the same way. And confirm the client wants all three layers, because the partner will use TAM to judge whether the theme deserves capital and SOM to underwrite the exit.

Build the TAM and explicitly call it a fantasy ceiling

India has roughly 1.4 billion people, of whom adults aged 25 and above are roughly 45 percent, about 620 million people, since preventive checkups are not sold to children. If every one of those adults took one annual checkup at an average package price of about 2,000 rupees, TAM would be 620 million times 2,000, or roughly 1.24 lakh crore rupees a year. State immediately that this is a theoretical ceiling and nothing more: it assumes universal ability to pay and universal preventive-health behaviour in a country where most diagnostic spend is reactive and out of pocket. Its only job is to tell the partner the theme is structurally large, and then to be discarded.

Cut to SAM with four filters, each stated as a business constraint

Filter one, ability to pay: a discretionary 2,000 to 4,000 rupee health spend needs household income above roughly 6 lakh rupees a year, which is broadly the top 12 to 15 percent of Indian households, about 40 million households, and at roughly 2.2 adults aged 25-plus per household that is about 90 million adults. Filter two, logistics reach: an organised chain needs sample-collection density and a cold chain, which today realistically covers metros and Tier-1 and larger Tier-2 towns, roughly 55 percent of that affluent base, so about 50 million adults. Filter three, actual behaviour: only a minority of even affluent adults do an annual preventive package rather than one-off prescribed tests, and post-COVID a fair estimate is about 40 percent, giving about 20 million checkup buyers, at roughly 1.15 packages a year each, or about 23 million checkups. Filter four, organised versus standalone: organised chains hold roughly 45 percent of Indian diagnostics overall but skew higher in packaged preventive products, call it 55 percent, leaving about 12.6 million organised checkups.

Cross-check the SAM, find the broken assumption, and fix it in front of the partner

At the entry price of 2,000 rupees, 12.6 million checkups gives about 2,500 crore rupees, but the known benchmark is that Indian diagnostics is roughly 80,000 crore rupees and preventive or wellness is usually put at 10 to 12 percent of it, so 8,000 to 9,000 crore. A three to four times gap means an input is wrong, and hunting it is more valuable than defending the number. Two assumptions break: 2,000 rupees is the entry-level package price while the affluent segment that actually buys skews to 3,000 to 5,000 rupee comprehensive panels, so blended realisation is closer to 3,200 rupees, and the corporate channel was ignored entirely even though employer-paid annual checkups are a large, separately contracted flow. Recomputing at 12.6 million checkups times 3,200 rupees gives about 4,000 crore rupees of retail, plus roughly 1,000 to 1,200 crore of corporate, so SAM is about 5,000 crore rupees, now within sensible distance of the benchmark and reconcilable by the fact that the benchmark bundles some prescribed wellness testing we deliberately excluded.

Estimate SOM from reach, not from ambition

Anchor share on physical assets, not on a chosen percentage. The chain has 180 collection centres against national leaders operating well over 2,500 to 3,000 collection points, so its national reach is roughly 6 percent, but its share is not national, it is concentrated in 4 states that represent roughly 28 percent of the national SAM, about 1,400 crore rupees. Within those 4 states it is the number two player with roughly 14 percent of organised preventive today, and the plan is to go from 180 to 400 centres plus a home-collection phlebotomist fleet and a dedicated corporate sales team, which supports pushing to about 18 percent by year three. That gives 1,400 crore times 18 percent, about 250 crore rupees of retail preventive revenue, plus roughly 60 crore from corporate contracts, so a year-three SOM near 310 crore rupees.

Cross-check bottom-up and pressure-test the throughput assumption

Rebuild from the outlet: 400 collection centres, each doing about 8 preventive package draws a day on top of its ordinary prescribed-test walk-ins, across roughly 330 operating days, is about 1.06 million checkups, and at 3,200 rupees that is about 340 crore rupees. That sits within about 10 percent of the 310 crore top-down figure, so the two builds corroborate each other. The check also reveals where the answer is fragile: SOM moves far more with checkups per centre per day than with the size of the national market, because dropping from 8 to 6 draws a day takes revenue to roughly 255 crore without any change in market share. That is the single input to validate in diligence, using the existing 180 centres' actual daily package counts split by mature versus recently opened cohorts.

Flex the drivers and convert the number into an investment decision

Two sensitivities matter. Price: aggressive discounting by online-led players on standard panels could pull blended realisation from 3,200 to about 2,600 rupees, taking SOM to roughly 250 crore. Channel: if the corporate book doubles on the back of two or three large IT and BFSI accounts, SOM rises to about 370 crore. So the honest answer is a 250 to 370 crore range around a 310 crore base, versus 150 crore today, roughly a 27 percent revenue CAGR. At about 22 percent EBITDA margin that is roughly 68 crore of year-three EBITDA, and at a mid-teens to 18 times exit multiple typical for organised diagnostics that supports an enterprise value comfortably above the 800 crore entry, so the deal is worth pursuing.